Alcon and RxSight team up to develop light-adjustable cataract lenses

Alcon (NYSE: ALC) and RxSight, Inc. (NASDAQ: RXST) announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) for use following cataract surgery, according to a press release issued July 6, 2026.

Under the agreement, the two companies will combine RxSight's post-operative light-adjustable lens technology with Alcon's PCIOL optical designs to create a co-developed product intended to allow surgeons to fine-tune visual outcomes after cataract surgery.

RxSight will receive a $60 million upfront payment to begin development. The company could receive up to an additional $140 million in payments contingent on development and regulatory milestones. Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and will receive royalties on net sales.

"Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery," said David J. Endicott, Chief Executive Officer of Alcon. "Together with RxSight's technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery."

Ron Kurtz, President and Chief Executive Officer of RxSight, said the collaboration "will help accelerate its expansion across a wider base of patients."

You May Also Be Interested In

• CLSA Starts salesforce.com (CRM) at Hold (3)
• CLSA Starts Workday (WDAY) at Underperform (4)
• Cadrenal Therapeutics CMO resigns, separation terms disclosed